← Back to Search

Antibody-drug conjugate

TR1801-ADC for Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by Open Innovation Partners, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3.5 years
Awards & highlights

Summary

This trial tests TR1801-ADC, an experimental drug, in patients with certain solid tumors that have the c-Met marker. The drug aims to kill cancer cells by targeting the c-Met marker.

Eligible Conditions
  • Unspecified Adult Solid Tumor Protocol Specific

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Characterize safety of TR1801-ADC in patients with advanced solid tumor malignancies which express c-Met
Establish maximum tolerated dose
Secondary study objectives
Evaluate clinical activity of TR1801-ADC
Evaluate pharmacokinetics of TR1801-ADC
Immunogenicity

Trial Design

1Treatment groups
Experimental Treatment
Group I: TR1801-ADCExperimental Treatment1 Intervention
Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin

Find a Location

Who is running the clinical trial?

Open Innovation Partners, Inc.Lead Sponsor
Tanabe Research Laboratories USA IncLead Sponsor
Open Innovation PartnersUNKNOWN
~2 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top